Cabilly patent overturned; FDA wants new Xolair warning; Avastin sales threatened.
|
U.S. Presidential candidate proposes legislation that would help bring generic versions of biotech drugs to market.
|
Diagnostic test may predict whether breast cancer will spread.
|
The company’s implant for treating depression fails to get Medicare reimbursement backing.
|
Medical device maker sees profit, shares dip.
|
FDA panel says rival device ineffective, but depression treatment maker not out of woods yet.
|
The med-tech giant’s shares tick upward as defibrillator market stabilizes.
|
Former FDA commissioner Mark McClellan wants business to take an active role in shaping health legislation.
|
Year in Review: Innovation and controversy defined the medical technology industry.
|
If only for a moment, Wall Street thought it knew where to place bets in the fierce competition between the only U.S. heart stent makers.
|
The agency proposes new regulations for use of experimental drugs.
|
The U.S. federal government starts a two day look into the rising safety concerns surrounding the more than $5 billion drug-coated stent industry.
|
The U.S. government weighs into the heated discussion over safety concerns plaguing the more than $5 billion drug-coated stent industry.
|
Federal agency plans to deregulate genetically engineered rice.
|
Med-tech maker’s top executive steps down following options inquiry.
|
The med-tech maker’s top exec steps down after options probe.
|
Analysts speculate billionaire Carl Icahn may soon target the management of the controversial medical technology company.
|
The federal agency publishes plan that could improve post-market device safety.
|
Shareholders are taking their push for changing the med-tech company’s board members to court.
|
The pharma company launches the world’s first novel combination drug for asthma.
|
Page
1
of
8
|